Pharmaceuticals News

Browse the latest Pharmaceuticals news. Use the menu or navigation tiles to change industry or topic.

January 26, 2026 02:21 ET | Source: Bavarian Nordic A/S

Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram

KØBENHAVN, Danmark, 26. januar 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggør transaktioner under aktietilbagekøbsprogrammet, der blev iværksat den 7. januar 2026, hvorunder selskaber vil...
January 26, 2026 02:21 ET | Source: Bavarian Nordic A/S

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

COPENHAGEN, Denmark, January 26, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase...
January 26, 2026 02:00 ET | Source: Scancell Holdings Plc

Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma

Unlocks path towards registrational Phase 3 trial planned to start in 2026 Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine standard of care (SoC) iSCIB1+ shows an interim...
January 26, 2026 01:30 ET | Source: HighLife

HighLife Receives CE Mark Approval for its TMVR Solution

HighLife Receives CE Mark Approval for its TMVR Solution
January 25, 2026 23:36 ET | Source: Vivani Medical, Inc.

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

ALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...
January 25, 2026 18:30 ET | Source: Biogen Inc.

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA...
January 23, 2026 17:25 ET | Source: Immunovant Inc.

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and...
January 23, 2026 17:00 ET | Source: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized...
January 23, 2026 16:15 ET | Source: Roivant Sciences

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday,...
January 23, 2026 16:10 ET | Source: XTL Biopharmaceuticals Ltd.

XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency

RAMAT GAN, ISRAEL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter...